These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38927219)

  • 21. Results from the Survey of Antibiotic Resistance (SOAR) 2015-18 in Tunisia, Kenya and Morocco: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
    Torumkuney D; Hammami A; Mezghani Maalej S; Ayed NB; Revathi G; Zerouali K; Elmdaghri N; Gachii AK; Morrissey I
    J Antimicrob Chemother; 2020 Apr; 75(Suppl 1):i2-i18. PubMed ID: 32337595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro Antimicrobial Activity and Dose Optimization of Eravacycline and Other Tetracycline Derivatives Against Levofloxacin-Non-Susceptible and/or Trimethoprim-Sulfamethoxazole-Resistant
    Wu J; Zhang G; Zhao Q; Wang L; Yang J; Cui J
    Infect Drug Resist; 2023; 16():6005-6015. PubMed ID: 37705512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the Performance of Manual Antimicrobial Susceptibility Testing Methods and Disk Breakpoints for
    Khan A; Pettaway C; Dien Bard J; Arias CA; Bhatti MM; Humphries RM
    Antimicrob Agents Chemother; 2023 May; 95(5):. PubMed ID: 33558287
    [No Abstract]   [Full Text] [Related]  

  • 24. Emerging infections in vulnerable hosts: Stenotrophomonas maltophilia and Elizabethkingia anophelis.
    Lee YL; Hsueh PR
    Curr Opin Infect Dis; 2023 Dec; 36(6):481-494. PubMed ID: 37548375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Results from the Survey of Antibiotic Resistance (SOAR) 2016-17 in Ukraine: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
    Torumkuney D; Bratus E; Yuvko O; Pertseva T; Morrissey I
    J Antimicrob Chemother; 2020 Apr; 75(Suppl 1):i100-i111. PubMed ID: 32337596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the Vitek 2, Phoenix, and MicroScan for Antimicrobial Susceptibility Testing of Stenotrophomonas maltophilia.
    Khan A; Arias CA; Abbott A; Dien Bard J; Bhatti MM; Humphries RM
    J Clin Microbiol; 2021 Aug; 59(9):e0065421. PubMed ID: 34011524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Role of New Posaconazole Formulations in the Treatment of Candida albicans Infections: Data from an
    Beredaki MI; Arendrup MC; Andes D; Mouton JW; Meletiadis J
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33468486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In-vitro pharmacokinetic/pharmacodynamic model data suggest a potential role of new formulations of posaconazole against Candida krusei but not Candida glabrata infections.
    Beredaki MI; Arendrup MC; Mouton JW; Meletiadis J
    Int J Antimicrob Agents; 2021 Mar; 57(3):106291. PubMed ID: 33508404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection.
    Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A
    Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of potential old and new drugs against multidrug-resistant gram-negatives.
    Rizek C; Ferraz JR; van der Heijden IM; Giudice M; Mostachio AK; Paez J; Carrilho C; Levin AS; Costa SF
    J Infect Chemother; 2015 Feb; 21(2):114-7. PubMed ID: 25456893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minocycline pharmacodynamics against Stenotrophomonas maltophilia in the neutropenic murine infection model: implications for susceptibility breakpoints.
    Fratoni AJ; Nicolau DP; Kuti JL
    J Antimicrob Chemother; 2022 Mar; 77(4):1052-1060. PubMed ID: 35134195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results from the Survey of Antibiotic Resistance (SOAR) 2015-17 in Turkey: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
    Torumkuney D; Tunger A; Sancak B; Bıçakçıgil A; Altun B; Aktas Z; Kayacan C; Morrissey I
    J Antimicrob Chemother; 2020 Apr; 75(Suppl 1):i88-i99. PubMed ID: 32337598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro combination of tigecycline with other antibiotics in Stenotrophomonas maltophilia isolates.
    Karamanlıoğlu D; Dizbay M
    Turk J Med Sci; 2019 Apr; 49(2):683-686. PubMed ID: 30866602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are oral cefuroxime axetil, cefixime and cefditoren pivoxil adequate to treat uncomplicated acute pyelonephritis after switching from intravenous therapy? A pharmacokinetic/pharmacodynamic perspective.
    Rodríguez-Gascón A; Aguirre-Quiñonero A; Canut-Blasco A
    Enferm Infecc Microbiol Clin (Engl Ed); 2020; 38(7):306-311. PubMed ID: 32085928
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Valero A; Rodríguez-Gascón A; Isla A; Barrasa H; Del Barrio-Tofiño E; Oliver A; Canut A; Solinís MÁ
    Pharmaceutics; 2021 Nov; 13(11):. PubMed ID: 34834314
    [No Abstract]   [Full Text] [Related]  

  • 36. Evaluation of the adequacy of the antimicrobial therapy of invasive Haemophilus influenzae infections: A pharmacokinetic/pharmacodynamic perspective.
    Ibar-Bariain M; Rodríguez-Gascón A; Isla A; Solinís MÁ; Canut-Blasco A
    Enferm Infecc Microbiol Clin (Engl Ed); 2021 Feb; 39(2):65-71. PubMed ID: 32636039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multicenter surveillance of antimicrobial resistance on Stenotrophomonas maltophilia in Taiwan.
    Wu H; Wang JT; Shiau YR; Wang HY; Lauderdale TL; Chang SC;
    J Microbiol Immunol Infect; 2012 Apr; 45(2):120-6. PubMed ID: 22154599
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breakpoints for carbapenemase-producing Enterobacteriaceae: is the problem solved?
    Cantón R; Canut A; Morosini MI; Oliver A
    Enferm Infecc Microbiol Clin; 2014 Dec; 32 Suppl 4():33-40. PubMed ID: 25542050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meropenem dosing requirements against Enterobacteriaceae in critically ill patients: influence of renal function, geographical area and presence of extended-spectrum β-lactamases.
    Isla A; Canut A; Arribas J; Asín-Prieto E; Rodríguez-Gascón A
    Eur J Clin Microbiol Infect Dis; 2016 Mar; 35(3):511-9. PubMed ID: 26782093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro.
    Lin Q; Zou H; Chen X; Wu M; Ma D; Yu H; Niu S; Huang S
    BMC Microbiol; 2021 Feb; 21(1):60. PubMed ID: 33618662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.